Journal article
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
Abstract
The survival benefit of combination chemotherapy to patients with advanced non-small-cell carcinoma of the lung (NSCLC) is controversial. To study this question, the National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a prospective randomized trial comparing best supportive care (BSC) to two chemotherapy regimens, vindesine and cisplatin (VP), and cyclophosphamide, doxorubicin, and cisplatin (CAP). Between February 1983 …
Authors
Rapp E; Pater JL; Willan A; Cormier Y; Murray N; Evans WK; Hodson DI; Clark DA; Feld R; Arnold AM
Journal
Journal of Clinical Oncology, Vol. 6, No. 4, pp. 633–641
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
April 1988
DOI
10.1200/jco.1988.6.4.633
ISSN
0732-183X